News
12-14-2010, 02:01 AM
Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.
More... (http://www.news-medical.net/news/20101214/Nektar-reports-positive-results-from-NKTR-102-Phase-2-study-in-metastatic-breast-cancer-at-CTRC-AACR-SABCS.aspx)
More... (http://www.news-medical.net/news/20101214/Nektar-reports-positive-results-from-NKTR-102-Phase-2-study-in-metastatic-breast-cancer-at-CTRC-AACR-SABCS.aspx)